SEATTLE--(BUSINESS WIRE)--Qiming Venture Partners USA (Qiming US), announced today the promotions of two key members of its investment team. Anna French, DPhil, based in the Boston area office and Colin Walsh, PhD, based in the San Francisco Bay area office were promoted to partner from their prior positions as principals.
“We are proud of the accomplishments and advancement of our two new Qiming US partners. Anna and Colin clearly represent the next generation of leadership for our growing healthcare fund,” said Gary Rieschel, Qiming US co-founder and partner. “Their expertise and sound judgement have distinguished them as key leaders within the organization. Both have been instrumental in the growth of our team and our investments. We look forward to their ongoing contributions.”
“Adding Anna and Colin as partners underscores the importance of diversity as well as the strong technical and operating competencies driving our investment process,” noted Mark McDade, Qiming US co-founder and partner. “In a short period of time, both sourced, led and closed multiple new investments in our core conviction areas while significantly expanding our overall global network and relationships.”
Dr. French joined Qiming US in 2017. She currently serves on the boards of WindMIL Therapeutics, Jasper Therapeutics and Umoja Biopharma, as well as a number of seed stage companies. She is also a board observer for several Qiming US portfolio companies. Anna was instrumental in the 2019 raise of the Qiming US Healthcare Fund II. Prior to joining Qiming US, Anna was a management consultant at the Boston Consulting Group (BCG) where she advised leading biopharma companies on strategy and operations. Before joining BCG, Anna led a global industry-academic consortium focused on cell therapy commercialization.
Dr. Walsh joined Qiming US in April 2019. He currently serves on the boards of Elevation Oncology and Korro Bio and is a board observer of Amphivena Therapeutics and Icosavax. Before joining Qiming US, Colin was a Vice President on the life science investment team at ND Capital where he sourced, structured, and managed investments in biotech, biopharma, and platform companies. Prior to ND, he held several roles as an early employee at Precision NanoSystems, a 5AM Ventures backed biotech developing a suite of technologies to enable the development of RNA-based therapeutics and other complex drug formulations.
About Qiming Venture Partners USA
Qiming Venture Partners was founded in China in 2006 and has over $5.5 billion in total assets under management. In January 2017, Qiming launched its first US-based fund, focused on early-stage healthcare opportunities in the United States and Europe. Situated in the major life science hubs of Cambridge, the San Francisco Bay Area and Seattle, we invest in highly disruptive platforms and products addressing significant unmet medical needs, driven by passionate and committed teams with the depth and experience to succeed. For more information visit https://www.qimingvcusa.com/.
